Panelists discuss how adverse effects associated with corticosteroids can significantly affect patient adherence and quality of life, emphasizing the need for future therapies to strike a balance between efficacy and a more tolerable adverse effect profile.
Panelists discuss how current treatments for IgA nephropathy often fall short in addressing the root cause, specifically abnormal IgA production and deposition, and highlight the consequences of prioritizing symptom management, such as proteinuria reduction, over targeting the disease’s underlying pathology.
Panelists discuss how the current treatment landscape for IgA nephropathy presents significant unmet needs, particularly in addressing the underlying causes of the disease and improving patient outcomes.
Panelists discuss how clinicians can effectively shift treatment strategies for IgA nephropathy from merely managing symptoms to actively targeting the root causes of the disease.
Panelists discuss how the reduction of proteinuria is integral to the broader treatment goals for IgA nephropathy, highlighting evidence that supports its role in preventing long-term kidney damage.
Panelists discuss how the primary treatment goals for patients with IgA nephropathy evolve based on the stage of the disease, emphasizing the importance of tailoring strategies to individual patient needs.
Panelists discuss how integrating additional biomarkers with proteinuria measurements can enhance the diagnostic accuracy for IgA nephropathy.
In the final segment of this episode, the discussion focuses on next steps for the PARASOL Initiative and its potential to transform FSGS drug development.
In part 3 of 4 from this episode, the discussion focuses on establishing surrogate endpoints for clinical trials in focal segmental glomerulosclerosis.
In part 2 of 4 from this episode, the discussion focuses on the groundbreaking work of the RADAR Registry and the PARASOL Initiative.
In part 1 of 4 from this episode, the discussion focuses on the backgrounds of guests Laura Mariani, MD, MS, and Daniel Gale, PhD, MB BChir.
This 4-part episode focuses on the PARASOL Initiative and the landscape of focal segmental glomerulosclerosis treatment.
Panelists discuss how clinicians determine the significance of proteinuria in assessing patients for potential IgA nephropathy (IgAN), including the levels and patterns that prompt further investigation and the specific diagnostic red flags that may suggest IgAN over other kidney disorders.
Panelists discuss how clinicians determine the significance of proteinuria in assessing patients for potential IgA nephropathy (IgAN), including the levels and patterns that prompt further investigation and the specific diagnostic red flags that may suggest IgAN over other kidney disorders.
Panelists discuss how clinicians can differentiate IgA nephropathy from other glomerular diseases, such as lupus nephritis and membranous nephropathy, that may present with similar clinical features.
Panelists discuss how misdiagnosis and delayed diagnosis of IgA nephropathy occur, highlighting the primary barriers to timely detection and strategies to overcome these challenges.
Panelists discuss how IgA nephropathy affects patients’ quality of life, addressing both the physical symptoms and the emotional challenges associated with the condition.
Panelists discuss the importance of screening and monitoring family members of individuals with IgA nephropathy, noting that up to 15% of cases are familial and outlining recommendations for the frequency of such assessments.
Panelists discuss potential biomarkers and clinical indicators that can aid in predicting disease outcomes for individual patients with IgA nephropathy.
Panelists discuss the immune system dysregulation underlying IgA nephropathy and highlight how this mechanism differs from those seen in other glomerular diseases.
Panelists discuss the progressive nature of immunoglobulin AIgA nephropathy (IgAN) and identify key factors that may accelerate its progression toward end-stage renal disease (ESRD).
Panelists discuss how IgA nephropathy presents in patients, often remaining asymptomatic until significant progression occurs, and explore the various subtypes that exhibit distinct clinical features.
Katherine Tuttle, MD, joins the podcast for a deep dive into the latest FLOW data from Kidney Week 2024.
Hiddo Heerspink, PhD, PharmD, joins the podcast during Kidney Week 2024 to discuss the SMART trial and the potential of semaglutide in people with kidney disease without diabetes.
Neuen, Wadhwani, and Barratt discuss atacicept promise in IgA nephropathy based on phase 2b ORIGIN OLE results, at-home use, and the future of kidney disease care.
Kidney Compass: Navigating Clinical Trials is a multimedia podcast from HCPLive hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, aimed at exploring the latest in clinical trials and updates in nephrology.
